• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
Home
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Pharma
    • Asia
    • Drug Delivery
    • Executives
    • Clinical Data
  • Vaccines
  • Special Reports
  • Trending
    • COVID-19
    • Cell & Gene Therapy
  • Podcasts
  • Resources
    • Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
Search Icon
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Pharma
    • Asia
    • Drug Delivery
    • Executives
    • Clinical Data
  • Vaccines
  • Special Reports
  • Trending
    • COVID-19
    • Cell & Gene Therapy
  • Podcasts
  • Resources
    • Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events

Exondys 51

Marketing

NS Pharma Duchenne drug wins speedy FDA nod to challenge Sarepta

FDA handed NS Pharma’s Viltepso a speedy FDA nod based on the same dystrophin production data that supported two Sarepta drugs' approvals.
Angus Liu Aug 13, 2020 11:34am

Sarepta's new DMD drug wins FDA nod in surprising reversal

Dec 13, 2019 10:03am

Sarepta's Exondys therapy not cost-effective for patients: ICER

May 23, 2019 12:06pm

CHMP endorses Lilly's CGRP Emgality, Spark's Luxturna and more

Sep 21, 2018 11:58am

Sarepta CEO Ingram nabs $57M in 2017 pay

May 7, 2018 12:36pm

Sarepta’s CEO pick draws praise, takeover talk from analysts

Jun 29, 2017 5:58am
Home
  • Connect
    • The Team
    • Advertise
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
  • ©2022 Questex LLC All rights reserved.
  • Terms of use
  • Privacy Policy